Digestive Enzymes
Replacement enzymes that work when your pancreas can't make enough.
What is Digestive Enzymes?
Digestive Enzymes (Pancreatin / proteases) is a gut and immune supplement used for correct fat & protein malabsorption. NutriDex grades the human evidence as Moderate. Digestive enzyme products supply the lipase, protease and amylase the pancreas normally secretes, plus sometimes lactase. As prescription pancreatic enzyme replacement therapy (PERT), they have robust evidence in exocrine pancreatic insufficiency: a meta-analysis of 14 RCTs (511 patients) found PERT raised the coefficient of fat absorption from ~63% to ~84% versus baseline and improved weight, symptoms and quality of life. In advanced pancreatic cancer with insufficiency, PERT was linked to ~3.8 months longer median survival in pooled data, though randomized results are less consistent. Standalone lactase reliably cuts symptoms and breath hydrogen in lactose intolerance. For the common OTC pitch — bloating and indigestion in people with healthy pancreases — only small 40–120-person trials over ~2 months show modest symptom relief. Effect requires taking enzymes with the meal, and benefit outside true deficiency states is unproven.
Purported Benefits
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Correct fat malabsorption in pancreatic insufficiencyMeta-analyses of RCTs show PERT raises fat absorption from ~63% to ~84% in exocrine pancreatic insufficiency. | Strong | ↑ benefit · large | 2 |
| Maintain weight and nutrition in insufficiencyMeta-analysis (14 RCTs, 511 patients) found PERT improved weight, symptoms and quality of life vs baseline. | Strong | ↑ benefit · moderate | 1 |
| Lactase relieves lactose intoleranceCrossover RCT shows oral lactase cuts symptoms and breath-hydrogen vs placebo in lactose intolerance. | Moderate | ↑ benefit · moderate | 1 |
| Ease bloating/dyspepsia in healthy pancreasesTwo small 40-120-person RCTs over ~2 months show modest symptom relief; benefit outside deficiency unproven. | Preliminary | ↑ benefit · small | 2 |
| Extend survival in advanced pancreatic cancerPooled data link PERT to ~3.8 months longer median survival, but randomized results are less consistent. | Preliminary | ↑ benefit · moderate | 1 |